Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10441164 | 0.91 | FAAH (0.62) | ACEFAAHNAALAD2MME | |
| SCHEMBL16892796 | 0.87 | ACE (0.58) | ACEFAAHNAALAD2MMENPSR1 | |
| SCHEMBL23376907 | 0.86 | MMP1 (0.56) | — | |
| SCHEMBL17261298 | 0.86 | NAALAD2 (0.68) | ACENAALAD2MMENPSR1LMNA | |
| SCHEMBL17624790 | 0.86 | NAALAD2 (0.68) | ACENAALAD2MMENPSR1LMNA | |
| SCHEMBL2806565 | 0.84 | FAAH (0.67) | ACEFAAHNAALAD2 | |
| SCHEMBL2806570 | 0.84 | FAAH (0.67) | ACEFAAHNAALAD2 | |
| SCHEMBL1330423 | 0.83 | ACE (0.63) | ACEFAAHNAALAD2MMENPSR1 | |
| SCHEMBL4153101 | 0.83 | ITGB3 (0.65) | ACEFAAHNAALAD2MMENPSR1 | |
| SCHEMBL5458748 | 0.83 | ITGB3 (0.65) | ACEFAAHNAALAD2MMENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011011766-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ACE 120/4885FAAH 400/4885NAALAD2 134/4885 |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ACE 120/4885FAAH 400/4885NAALAD2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.